Katabami T, et al. - Using the Japan Primary Aldosteronism Study database, researchers examined patients (n=339) with unilateral primary aldosteronism confirmed by adrenal vein sampling to assess the impacts of adrenalectomy (AdX) vs medical therapy. Overall 276 patients (AdX group) received unilateral AdX and 63 patients were treated with mineral corticoid receptor antagonists (MRAs; MRAs group). The AdX group vs the MRAs group demonstrated superior clinical and biochemical outcome at 6 months following initiation of specific treatment for primary aldosteronism, therefore, in patients with unilateral primary aldosteronism, AdX represents the first choice of therapy, as per evidence gained in this study.